Alcon breaks off research deal with Angiotech
This article was originally published in Clinica
Executive Summary
Ophthalmic giant Alcon has announced it plans to end its research collaboration with Canadian company Angiotech Pharmaceuticals involving coatings for therapeutic implants, as the lead formulation developed by the two companies did not meet required criteria to continue to the human trial stage.